Prostate Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020

All the vital news, analysis, and commentary curated by our industry experts.

$4000

Buy Report View Sample

Published: November 30, 2020 Report Code: GDME1049EPD-ST

Report Overview
Key Players
Table of Contents
Table
Figures

Prostate Cancer Diagnostic Tests include assays of mostly antibodies released in response to a prostate cancer and cancer-causing proteins. GlobalData's Medical Devices sector report, “Prostate Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Prostate Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
The Prostate Cancer Diagnostic Tests Pipeline Assessment report provides key information and data related to:
Extensive coverage of the Prostate Cancer Diagnostic Tests under development
Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates
Reviews of major players involved in the pipeline product development.
Provides key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and, the number of trials of the major Prostate Cancer Diagnostic Tests pipeline products.
Review of Recent Developments in the segment / industry
The Prostate Cancer Diagnostic Tests Pipeline Assessment report enables you to:
Access significant competitor information, analysis, and insights to improve your R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of Prostate Cancer Diagnostic Tests under development
Formulate market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
The major companies covered in the “Prostate Cancer Diagnostic Tests- Medical Devices Pipeline Assessment, 2020” report:
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
The GlobalData Differentiation

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

The data and analysis within this report are driven by GlobalData Medical Intelligence Center (GDMIC) database. GDMIC gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following:

• 15,000+ data tables showing market size across more than 780 medical equipment segments and 39 countries, from 2015 and forecast to 2025
• 6,700+ industry-leading analysis reports covering sector reports, medipoint reports, country analysis, expert insights and industry analysis (devices and procedures) reports
• 64,000+ medical equipment company profiles
• 5,600+ company profiles of medical equipment manufacturers in China and India
• 2,200+ company profiles of medical equipment manufacturers in Japan
• 1,200+ companies’ revenue splits and market shares
• 1,600+ quarterly and annual medical equipment company financials
• 850+ medical equipment company SWOTs
• 28,000+ pipeline product profiles
• 56,400+ marketed product profiles
• 47,000+ clinical trials
• 41,500+ trial investigators
• 7,000+ reports on companies with products in development
• 44,000+ deals in the medical equipment industry
• 1,100+ surgical and diagnostic procedures by therapy area
• 50+ key healthcare indicators by country
• 431,000+ Themes Content Items
• 600+ Influencers
• 1,900+ Analysts & Researchers
• 0.5m+ Community Members
• 141,000+ Macroeconomic Indicators
• 1,013,000+ City Indicators

For more information or to receive a free demonstration of the service, please visit:
https://medical.globaldata.com/home.aspx
Custom Requirements
Contact us to discuss the areas of your business where you need external input, and we will work with you to identify the strongest way forward to meet your needs.

Scope

– Extensive coverage of the Prostate Cancer Diagnostic Tests under development

– The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

– The report reviews the major players involved in the development of Prostate Cancer Diagnostic Tests and list all their pipeline projects

– The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

– The report provides key clinical trial data of ongoing trials specific to pipeline products

– Recent developments in the segment / industry

Reasons to Buy

The report enables you to:

– Formulate significant competitor information, analysis, and insights to improve R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of Prostate Cancer Diagnostic Tests under development

– Develop market-entry and market expansion strategies

– Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

– In-depth analysis of the product’s current stage of development, territory and estimated launch date

3D Biomatrix LLC
A&G Pharmaceutical Inc
Abnova Corp
AccuTech LLC
Acobiom
Advanced Marker Discovery SL
Affinimark Technologies
Inc.
AIT Austrian Institute of Technology GmbH
Albert Ludwigs University of Freiburg
Alere Inc
Almac Diagnostic Services Ltd
Andro Diagnostics (Inactive)
Anixa Diagnostics Corporation
Armune BioScience Inc
Arno Therapeutics Inc
Arquer Diagnostics Ltd
Arrayit Corporation
Atrys Health SA
Atturos
Aurelium BioPharma Inc.
BARD1 Life Sciences Ltd
Baylor College of Medicine
Beckman Coulter Inc
Berg LLC
BioAffinity Technologies
Inc.
Biocrates Life Sciences AG
BioMark Diagnostics Inc
bioMerieux SA
Biosceptre International Ltd
Biotron Ltd
Blondin Bioscience
LLC
Boditech Med Inc
Boston Children's Hospital
Caldera Health Ltd
Cambridge Oncometrix Ltd
Cancer Research Technology Ltd
Cancer Research UK Manchester Institute
Caris Life Sciences Inc
Cellanyx Diagnostics
Inc.
Cellmid Ltd
Cepheid Inc
Ceres Nanosciences Inc
ChemImage Corp
China Sky One Medical Inc
Chronix Biomedical Inc
Cleveland Diagnostics Inc.
CompanDX Ltd
Contango Asset Management Ltd
Cornell University
Courtagen Life Sciences Inc
CS-Keys
Inc. (Inactive)
Cytosystems Ltd
Detroit R&D
Inc.
Elypta AB
Emory University
Entopsis LLC
Epigenomics AG
Euclid Diagnostics LLC
Eurobio Scientific SA
Eventus Diagnostics Inc (Inactive)
Exact Sciences Corp
Exiqon AS
Exosome Diagnostics Inc
Exosomics Siena SpA
Fluxion Biosciences Inc
Fred Hutchinson Cancer Research Center
French National Institute of Health and Medical Research
Genomic Health Inc
Georgia Institute of Technology
Gilupi GmbH
GlyCa BioSciences Inc
GlycoZym USA Inc
Gregor Diagnostics Inc
H. Lee Moffitt Cancer Center & Research Institute Inc
HealthTell Inc
Hologic Inc
Ikonisys Inc
Imagion Biosystems Inc
Immunovia AB
Imperial College London
InterGenetics Inc
IRIS International Inc
Johns Hopkins University
KineMed Inc
L2 Diagnostics LLC
Lantern Pharma Inc
Lynx Design
Inc.
MabCure Inc
MacroArray Technologies LLC
MDNA Life Sciences Inc
MDxHealth SA
Metabolomic Technologies Inc
Metanomics Health GmbH
MetaStat Inc
Micromedic Technologies Ltd
Milagen Inc
Minomic International Ltd
Myriad Genetics Inc
Myriad International GmbH
Nano Discovery Inc.
Nanocytomics LLC
NanoIVD Inc
Nanostics Inc
NeuroBioTex Inc
Nonagen Bioscience Corp
Northwestern University
NovaGray
Novel Bio-spectrum Technologies Inc (Inactive)
Nuclea Biotechnologies Inc. (Inactive)
Numares AG
NuView Life Sciences Inc
Olympia Diagnostics Inc
Oncimmune (USA) LLC
OncoCyte Corp
Onconome
Inc. (Inactive)
ONCOVEDA Cancer Research Center
OncoVista Innovative Therapies Inc
On-Q-ity
Inc. (Inactive)
Ontario Institute for Cancer Research
OPKO Health Inc
Oregon Health & Science University
Orion Genomics LLC
Ortho-Clinical Diagnostics Inc
Oryzon Genomics SA
OTraces Inc
Oxford Gene Technology Ltd
PharmaSeq Inc
Precision Biologics Inc
Predictive Biosciences Inc (Inactive)
Preora Healthcare Inc
PrognosDx Health Inc
Prostagnost
Prostate Management Diagnostics Inc
Protagen AG
Proteocyte Diagnostics Inc
ProteoMediX AG
Proteomika (Inactive)
Proveri Inc. (Inactive)
QIAGEN GmbH
Qiagen NV
Quanterix Corp
Quest Diagnostics Inc
Rappaport Family Institute for Research in the Medical Science
Rarecells
RiboMed Biotechnologies Inc
RISE Life Science Corp
Roche Diagnostics International Ltd
Roswell Park Cancer Institute
Siemens Healthcare Diagnostics Inc
Sienna Cancer Diagnostics Ltd
SomaLogic Inc
Soricimed Biopharma Inc
Source MDx
Stage I Diagnostics Inc
Target Discovery Inc
Thermo Fisher Scientific Inc
TRACON Pharmaceuticals Inc
UCD Conway Institute of Biomolecular and Biomedical Research
University College Dublin
University of Arizona
University of Birmingham
University of California Los Angeles
University of Central Florida
University of Cologne
University of Colorado
University of Connecticut
University of Gottingen
University of Malaya
University of Maryland Baltimore
University of Michigan
University of Newcastle
University of Oslo
University of Otago
University of South Australia
University of Strathclyde
University of Turku
University of Washington
Uppsala University
US Biomarkers Inc
Vala Sciences Inc
Vermillion Inc
Vitrimark Inc (Inactive)
Vitruvian Biomedical Inc
VolitionRX Ltd
X-Zell Inc
ZORA Biosciences Oy

1 Table of Contents 2

1.1 List of Tables 11

1.2 List of Figures 23

2 Introduction 24

2.1 Prostate Cancer Overview 24

3 Products under Development 25

3.1 Prostate Cancer – Pipeline Products by Stage of Development 25

3.2 Prostate Cancer – Pipeline Products by Territory 26

3.3 Prostate Cancer – Pipeline Products by Regulatory Path 27

3.4 Prostate Cancer – Pipeline Products by Estimated Approval Date 28

3.5 Prostate Cancer – Ongoing Clinical Trials 29

4 Prostate Cancer – Pipeline Products under Development by Companies 30

4.1 Prostate Cancer Companies – Pipeline Products by Stage of Development 30

4.2 Prostate Cancer – Pipeline Products by Stage of Development 37

5 Prostate Cancer Companies and Product Overview 43

5.1 3D Biomatrix LLC Company Overview 43

5.1.1 3D Biomatrix LLC Pipeline Products & Ongoing Clinical Trials Overview 43

5.2 A&G Pharmaceutical Inc Company Overview 44

5.2.1 A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 44

5.3 Abnova Corp Company Overview 45

5.3.1 Abnova Corp Pipeline Products & Ongoing Clinical Trials Overview 45

5.4 AccuTech LLC Company Overview 46

5.4.1 AccuTech LLC Pipeline Products & Ongoing Clinical Trials Overview 46

5.5 Acobiom Company Overview 47

5.5.1 Acobiom Pipeline Products & Ongoing Clinical Trials Overview 47

5.6 Advanced Marker Discovery SL Company Overview 48

5.6.1 Advanced Marker Discovery SL Pipeline Products & Ongoing Clinical Trials Overview 48

5.7 Affinimark Technologies, Inc. Company Overview 51

5.7.1 Affinimark Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 51

5.8 AIT Austrian Institute of Technology GmbH Company Overview 52

5.8.1 AIT Austrian Institute of Technology GmbH Pipeline Products & Ongoing Clinical Trials Overview 52

5.9 Albert Ludwigs University of Freiburg Company Overview 53

5.9.1 Albert Ludwigs University of Freiburg Pipeline Products & Ongoing Clinical Trials Overview 53

5.10 Alere Inc Company Overview 54

5.10.1 Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 54

5.11 Almac Diagnostic Services Ltd Company Overview 55

5.11.1 Almac Diagnostic Services Ltd Pipeline Products & Ongoing Clinical Trials Overview 55

5.12 Andro Diagnostics (Inactive) Company Overview 56

5.12.1 Andro Diagnostics (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 56

5.13 Anixa Diagnostics Corporation Company Overview 57

5.13.1 Anixa Diagnostics Corporation Pipeline Products & Ongoing Clinical Trials Overview 57

5.14 Armune BioScience Inc Company Overview 59

5.14.1 Armune BioScience Inc Pipeline Products & Ongoing Clinical Trials Overview 59

5.15 Arno Therapeutics Inc Company Overview 60

5.15.1 Arno Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 60

5.16 Arquer Diagnostics Ltd Company Overview 61

5.16.1 Arquer Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 61

5.17 Arrayit Corporation Company Overview 62

5.17.1 Arrayit Corporation Pipeline Products & Ongoing Clinical Trials Overview 62

5.18 Atrys Health SA Company Overview 63

5.18.1 Atrys Health SA Pipeline Products & Ongoing Clinical Trials Overview 63

5.19 Atturos Company Overview 64

5.19.1 Atturos Pipeline Products & Ongoing Clinical Trials Overview 64

5.20 Aurelium BioPharma Inc. Company Overview 65

5.20.1 Aurelium BioPharma Inc. Pipeline Products & Ongoing Clinical Trials Overview 65

5.21 BARD1 Life Sciences Ltd Company Overview 66

5.21.1 BARD1 Life Sciences Ltd Pipeline Products & Ongoing Clinical Trials Overview 66

5.22 Baylor College of Medicine Company Overview 67

5.22.1 Baylor College of Medicine Pipeline Products & Ongoing Clinical Trials Overview 67

5.23 Beckman Coulter Inc Company Overview 69

5.23.1 Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 69

5.24 Berg LLC Company Overview 70

5.24.1 Berg LLC Pipeline Products & Ongoing Clinical Trials Overview 70

5.25 BioAffinity Technologies, Inc. Company Overview 71

5.25.1 BioAffinity Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 71

5.26 Biocrates Life Sciences AG Company Overview 72

5.26.1 Biocrates Life Sciences AG Pipeline Products & Ongoing Clinical Trials Overview 72

5.27 BioMark Diagnostics Inc Company Overview 73

5.27.1 BioMark Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 73

5.28 bioMerieux SA Company Overview 75

5.28.1 bioMerieux SA Pipeline Products & Ongoing Clinical Trials Overview 75

5.29 Biosceptre International Ltd Company Overview 78

5.29.1 Biosceptre International Ltd Pipeline Products & Ongoing Clinical Trials Overview 78

5.30 Biotron Ltd Company Overview 80

5.30.1 Biotron Ltd Pipeline Products & Ongoing Clinical Trials Overview 80

5.31 Blondin Bioscience, LLC Company Overview 81

5.31.1 Blondin Bioscience, LLC Pipeline Products & Ongoing Clinical Trials Overview 81

5.32 Boditech Med Inc Company Overview 82

5.32.1 Boditech Med Inc Pipeline Products & Ongoing Clinical Trials Overview 82

5.33 Boston Children's Hospital Company Overview 83

5.33.1 Boston Children's Hospital Pipeline Products & Ongoing Clinical Trials Overview 83

5.34 Caldera Health Ltd Company Overview 84

5.34.1 Caldera Health Ltd Pipeline Products & Ongoing Clinical Trials Overview 84

5.35 Cambridge Oncometrix Ltd Company Overview 85

5.35.1 Cambridge Oncometrix Ltd Pipeline Products & Ongoing Clinical Trials Overview 85

5.36 Cancer Research Technology Ltd Company Overview 88

5.36.1 Cancer Research Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 88

5.37 Cancer Research UK Manchester Institute Company Overview 89

5.37.1 Cancer Research UK Manchester Institute Pipeline Products & Ongoing Clinical Trials Overview 89

5.38 Caris Life Sciences Inc Company Overview 90

5.38.1 Caris Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 90

5.39 Cellanyx Diagnostics, Inc. Company Overview 91

5.39.1 Cellanyx Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 91

5.40 Cellmid Ltd Company Overview 92

5.40.1 Cellmid Ltd Pipeline Products & Ongoing Clinical Trials Overview 92

5.41 Cepheid Inc Company Overview 93

5.41.1 Cepheid Inc Pipeline Products & Ongoing Clinical Trials Overview 93

5.42 Ceres Nanosciences Inc Company Overview 95

5.42.1 Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 95

5.43 ChemImage Corp Company Overview 96

5.43.1 ChemImage Corp Pipeline Products & Ongoing Clinical Trials Overview 96

5.44 China Sky One Medical Inc Company Overview 97

5.44.1 China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 97

5.45 Chronix Biomedical Inc Company Overview 98

5.45.1 Chronix Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 98

5.46 Cleveland Diagnostics Inc. Company Overview 99

5.46.1 Cleveland Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 99

5.47 CompanDX Ltd Company Overview 100

5.47.1 CompanDX Ltd Pipeline Products & Ongoing Clinical Trials Overview 100

5.48 Contango Asset Management Ltd Company Overview 101

5.48.1 Contango Asset Management Ltd Pipeline Products & Ongoing Clinical Trials Overview 101

5.49 Cornell University Company Overview 102

5.49.1 Cornell University Pipeline Products & Ongoing Clinical Trials Overview 102

5.50 Courtagen Life Sciences Inc Company Overview 103

5.50.1 Courtagen Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 103

5.51 CS-Keys, Inc. (Inactive) Company Overview 104

5.51.1 CS-Keys, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 104

5.52 Cytosystems Ltd Company Overview 105

5.52.1 Cytosystems Ltd Pipeline Products & Ongoing Clinical Trials Overview 105

5.53 Detroit R&D, Inc. Company Overview 106

5.53.1 Detroit R&D, Inc. Pipeline Products & Ongoing Clinical Trials Overview 106

5.54 Elypta AB Company Overview 107

5.54.1 Elypta AB Pipeline Products & Ongoing Clinical Trials Overview 107

5.55 Emory University Company Overview 108

5.55.1 Emory University Pipeline Products & Ongoing Clinical Trials Overview 108

5.56 Entopsis LLC Company Overview 109

5.56.1 Entopsis LLC Pipeline Products & Ongoing Clinical Trials Overview 109

5.57 Epigenomics AG Company Overview 110

5.57.1 Epigenomics AG Pipeline Products & Ongoing Clinical Trials Overview 110

5.58 Euclid Diagnostics LLC Company Overview 111

5.58.1 Euclid Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 111

5.59 Eurobio Scientific SA Company Overview 112

5.59.1 Eurobio Scientific SA Pipeline Products & Ongoing Clinical Trials Overview 112

5.60 Eventus Diagnostics Inc (Inactive) Company Overview 113

5.60.1 Eventus Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 113

5.61 Exact Sciences Corp Company Overview 114

5.61.1 Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 114

5.62 Exiqon AS Company Overview 115

5.62.1 Exiqon AS Pipeline Products & Ongoing Clinical Trials Overview 115

5.63 Exosome Diagnostics Inc Company Overview 116

5.63.1 Exosome Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 116

5.64 Exosomics Siena SpA Company Overview 119

5.64.1 Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview 119

5.65 Fluxion Biosciences Inc Company Overview 120

5.65.1 Fluxion Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 120

5.66 Fred Hutchinson Cancer Research Center Company Overview 121

5.66.1 Fred Hutchinson Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 121

5.67 French National Institute of Health and Medical Research Company Overview 122

5.67.1 French National Institute of Health and Medical Research Pipeline Products & Ongoing Clinical Trials Overview 122

5.68 Genomic Health Inc Company Overview 123

5.68.1 Genomic Health Inc Pipeline Products & Ongoing Clinical Trials Overview 123

5.69 Georgia Institute of Technology Company Overview 125

5.69.1 Georgia Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 125

5.70 Gilupi GmbH Company Overview 126

5.70.1 Gilupi GmbH Pipeline Products & Ongoing Clinical Trials Overview 126

5.71 GlyCa BioSciences Inc Company Overview 127

5.71.1 GlyCa BioSciences Inc Pipeline Products & Ongoing Clinical Trials Overview 127

5.72 GlycoZym USA Inc Company Overview 128

5.72.1 GlycoZym USA Inc Pipeline Products & Ongoing Clinical Trials Overview 128

5.73 Gregor Diagnostics Inc Company Overview 129

5.73.1 Gregor Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 129

5.74 H. Lee Moffitt Cancer Center & Research Institute Inc Company Overview 130

5.74.1 H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 130

5.75 HealthTell Inc Company Overview 133

5.75.1 HealthTell Inc Pipeline Products & Ongoing Clinical Trials Overview 133

5.76 Hologic Inc Company Overview 134

5.76.1 Hologic Inc Pipeline Products & Ongoing Clinical Trials Overview 134

5.77 Ikonisys Inc Company Overview 135

5.77.1 Ikonisys Inc Pipeline Products & Ongoing Clinical Trials Overview 135

5.78 Imagion Biosystems Inc Company Overview 136

5.78.1 Imagion Biosystems Inc Pipeline Products & Ongoing Clinical Trials Overview 136

5.79 Immunovia AB Company Overview 137

5.79.1 Immunovia AB Pipeline Products & Ongoing Clinical Trials Overview 137

5.80 Imperial College London Company Overview 138

5.80.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 138

5.81 InterGenetics Inc Company Overview 139

5.81.1 InterGenetics Inc Pipeline Products & Ongoing Clinical Trials Overview 139

5.82 IRIS International Inc Company Overview 140

5.82.1 IRIS International Inc Pipeline Products & Ongoing Clinical Trials Overview 140

5.83 Johns Hopkins University Company Overview 141

5.83.1 Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 141

5.84 KineMed Inc Company Overview 146

5.84.1 KineMed Inc Pipeline Products & Ongoing Clinical Trials Overview 146

5.85 L2 Diagnostics LLC Company Overview 147

5.85.1 L2 Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 147

5.86 Lantern Pharma Inc Company Overview 148

5.86.1 Lantern Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview 148

5.87 Lynx Design, Inc. Company Overview 149

5.87.1 Lynx Design, Inc. Pipeline Products & Ongoing Clinical Trials Overview 149

5.88 MabCure Inc Company Overview 150

5.88.1 MabCure Inc Pipeline Products & Ongoing Clinical Trials Overview 150

5.89 MacroArray Technologies LLC Company Overview 151

5.89.1 MacroArray Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 151

5.90 MDNA Life Sciences Inc Company Overview 154

5.90.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 154

5.91 MDxHealth SA Company Overview 156

5.91.1 MDxHealth SA Pipeline Products & Ongoing Clinical Trials Overview 156

5.92 Metabolomic Technologies Inc Company Overview 160

5.92.1 Metabolomic Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 160

5.93 Metanomics Health GmbH Company Overview 161

5.93.1 Metanomics Health GmbH Pipeline Products & Ongoing Clinical Trials Overview 161

5.94 MetaStat Inc Company Overview 162

5.94.1 MetaStat Inc Pipeline Products & Ongoing Clinical Trials Overview 162

5.95 Micromedic Technologies Ltd Company Overview 163

5.95.1 Micromedic Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 163

5.96 Milagen Inc Company Overview 164

5.96.1 Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview 164

5.97 Minomic International Ltd Company Overview 165

5.97.1 Minomic International Ltd Pipeline Products & Ongoing Clinical Trials Overview 165

5.98 Myriad Genetics Inc Company Overview 167

5.98.1 Myriad Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 167

5.99 Myriad International GmbH Company Overview 168

5.99.1 Myriad International GmbH Pipeline Products & Ongoing Clinical Trials Overview 168

5.100 Nano Discovery Inc. Company Overview 169

5.100.1 Nano Discovery Inc. Pipeline Products & Ongoing Clinical Trials Overview 169

5.101 Nanocytomics LLC Company Overview 170

5.101.1 Nanocytomics LLC Pipeline Products & Ongoing Clinical Trials Overview 170

5.102 NanoIVD Inc Company Overview 171

5.102.1 NanoIVD Inc Pipeline Products & Ongoing Clinical Trials Overview 171

5.103 Nanostics Inc Company Overview 172

5.103.1 Nanostics Inc Pipeline Products & Ongoing Clinical Trials Overview 172

5.104 NeuroBioTex Inc Company Overview 175

5.104.1 NeuroBioTex Inc Pipeline Products & Ongoing Clinical Trials Overview 175

5.105 Nonagen Bioscience Corp Company Overview 176

5.105.1 Nonagen Bioscience Corp Pipeline Products & Ongoing Clinical Trials Overview 176

5.106 Northwestern University Company Overview 177

5.106.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 177

5.107 NovaGray Company Overview 178

5.107.1 NovaGray Pipeline Products & Ongoing Clinical Trials Overview 178

5.108 Novel Bio-spectrum Technologies Inc (Inactive) Company Overview 179

5.108.1 Novel Bio-spectrum Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 179

5.109 Nuclea Biotechnologies Inc. (Inactive) Company Overview 180

5.109.1 Nuclea Biotechnologies Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 180

5.110 Numares AG Company Overview 182

5.110.1 Numares AG Pipeline Products & Ongoing Clinical Trials Overview 182

5.111 NuView Life Sciences Inc Company Overview 183

5.111.1 NuView Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 183

5.112 Olympia Diagnostics Inc Company Overview 186

5.112.1 Olympia Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 186

5.113 Oncimmune (USA) LLC Company Overview 190

5.113.1 Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 190

5.114 OncoCyte Corp Company Overview 191

5.114.1 OncoCyte Corp Pipeline Products & Ongoing Clinical Trials Overview 191

5.115 Onconome, Inc. (Inactive) Company Overview 192

5.115.1 Onconome, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 192

5.116 ONCOVEDA Cancer Research Center Company Overview 194

5.116.1 ONCOVEDA Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 194

5.117 OncoVista Innovative Therapies Inc Company Overview 195

5.117.1 OncoVista Innovative Therapies Inc Pipeline Products & Ongoing Clinical Trials Overview 195

5.118 On-Q-ity, Inc. (Inactive) Company Overview 196

5.118.1 On-Q-ity, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 196

5.119 Ontario Institute for Cancer Research Company Overview 197

5.119.1 Ontario Institute for Cancer Research Pipeline Products & Ongoing Clinical Trials Overview 197

5.120 OPKO Health Inc Company Overview 198

5.120.1 OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 198

5.121 Oregon Health & Science University Company Overview 199

5.121.1 Oregon Health & Science University Pipeline Products & Ongoing Clinical Trials Overview 199

5.122 Orion Genomics LLC Company Overview 200

5.122.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 200

5.123 Ortho-Clinical Diagnostics Inc Company Overview 201

5.123.1 Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 201

5.124 Oryzon Genomics SA Company Overview 202

5.124.1 Oryzon Genomics SA Pipeline Products & Ongoing Clinical Trials Overview 202

5.125 OTraces Inc Company Overview 204

5.125.1 OTraces Inc Pipeline Products & Ongoing Clinical Trials Overview 204

5.126 Oxford Gene Technology Ltd Company Overview 205

5.126.1 Oxford Gene Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 205

5.127 PharmaSeq Inc Company Overview 206

5.127.1 PharmaSeq Inc Pipeline Products & Ongoing Clinical Trials Overview 206

5.128 Precision Biologics Inc Company Overview 207

5.128.1 Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview 207

5.129 Predictive Biosciences Inc (Inactive) Company Overview 208

5.129.1 Predictive Biosciences Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 208

5.130 Preora Healthcare Inc Company Overview 210

5.130.1 Preora Healthcare Inc Pipeline Products & Ongoing Clinical Trials Overview 210

5.131 PrognosDx Health Inc Company Overview 211

5.131.1 PrognosDx Health Inc Pipeline Products & Ongoing Clinical Trials Overview 211

5.132 Prostagnost Company Overview 212

5.132.1 Prostagnost Pipeline Products & Ongoing Clinical Trials Overview 212

5.133 Prostate Management Diagnostics Inc Company Overview 213

5.133.1 Prostate Management Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 213

5.134 Protagen AG Company Overview 215

5.134.1 Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 215

5.135 Proteocyte Diagnostics Inc Company Overview 216

5.135.1 Proteocyte Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 216

5.136 ProteoMediX AG Company Overview 217

5.136.1 ProteoMediX AG Pipeline Products & Ongoing Clinical Trials Overview 217

5.137 Proteomika (Inactive) Company Overview 220

5.137.1 Proteomika (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 220

5.138 Proveri Inc. (Inactive) Company Overview 221

5.138.1 Proveri Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 221

5.139 QIAGEN GmbH Company Overview 224

5.139.1 QIAGEN GmbH Pipeline Products & Ongoing Clinical Trials Overview 224

5.140 Qiagen NV Company Overview 226

5.140.1 Qiagen NV Pipeline Products & Ongoing Clinical Trials Overview 226

5.141 Quanterix Corp Company Overview 227

5.141.1 Quanterix Corp Pipeline Products & Ongoing Clinical Trials Overview 227

5.142 Quest Diagnostics Inc Company Overview 229

5.142.1 Quest Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 229

5.143 Rappaport Family Institute for Research in the Medical Science Company Overview 230

5.143.1 Rappaport Family Institute for Research in the Medical Science Pipeline Products & Ongoing Clinical Trials Overview 230

5.144 Rarecells Company Overview 231

5.144.1 Rarecells Pipeline Products & Ongoing Clinical Trials Overview 231

5.145 RiboMed Biotechnologies Inc Company Overview 232

5.145.1 RiboMed Biotechnologies Inc Pipeline Products & Ongoing Clinical Trials Overview 232

5.146 RISE Life Science Corp Company Overview 233

5.146.1 RISE Life Science Corp Pipeline Products & Ongoing Clinical Trials Overview 233

5.147 Roche Diagnostics International Ltd Company Overview 234

5.147.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 234

5.148 Roswell Park Cancer Institute Company Overview 235

5.148.1 Roswell Park Cancer Institute Pipeline Products & Ongoing Clinical Trials Overview 235

5.149 Siemens Healthcare Diagnostics Inc Company Overview 236

5.149.1 Siemens Healthcare Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 236

5.150 Sienna Cancer Diagnostics Ltd Company Overview 237

5.150.1 Sienna Cancer Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 237

5.151 SomaLogic Inc Company Overview 238

5.151.1 SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview 238

5.152 Soricimed Biopharma Inc Company Overview 239

5.152.1 Soricimed Biopharma Inc Pipeline Products & Ongoing Clinical Trials Overview 239

5.153 Source MDx Company Overview 241

5.153.1 Source MDx Pipeline Products & Ongoing Clinical Trials Overview 241

5.154 Stage I Diagnostics Inc Company Overview 243

5.154.1 Stage I Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 243

5.155 Target Discovery Inc Company Overview 244

5.155.1 Target Discovery Inc Pipeline Products & Ongoing Clinical Trials Overview 244

5.156 Thermo Fisher Scientific Inc Company Overview 245

5.156.1 Thermo Fisher Scientific Inc Pipeline Products & Ongoing Clinical Trials Overview 245

5.157 TRACON Pharmaceuticals Inc Company Overview 248

5.157.1 TRACON Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 248

5.158 UCD Conway Institute of Biomolecular and Biomedical Research Company Overview 249

5.158.1 UCD Conway Institute of Biomolecular and Biomedical Research Pipeline Products & Ongoing Clinical Trials Overview 249

5.159 University College Dublin Company Overview 250

5.159.1 University College Dublin Pipeline Products & Ongoing Clinical Trials Overview 250

5.160 University of Arizona Company Overview 251

5.160.1 University of Arizona Pipeline Products & Ongoing Clinical Trials Overview 251

5.161 University of Birmingham Company Overview 252

5.161.1 University of Birmingham Pipeline Products & Ongoing Clinical Trials Overview 252

5.162 University of California Los Angeles Company Overview 253

5.162.1 University of California Los Angeles Pipeline Products & Ongoing Clinical Trials Overview 253

5.163 University of Central Florida Company Overview 254

5.163.1 University of Central Florida Pipeline Products & Ongoing Clinical Trials Overview 254

5.164 University of Cologne Company Overview 255

5.164.1 University of Cologne Pipeline Products & Ongoing Clinical Trials Overview 255

5.165 University of Colorado Company Overview 256

5.165.1 University of Colorado Pipeline Products & Ongoing Clinical Trials Overview 256

5.166 University of Connecticut Company Overview 257

5.166.1 University of Connecticut Pipeline Products & Ongoing Clinical Trials Overview 257

5.167 University of Gottingen Company Overview 258

5.167.1 University of Gottingen Pipeline Products & Ongoing Clinical Trials Overview 258

5.168 University of Malaya Company Overview 259

5.168.1 University of Malaya Pipeline Products & Ongoing Clinical Trials Overview 259

5.169 University of Maryland Baltimore Company Overview 260

5.169.1 University of Maryland Baltimore Pipeline Products & Ongoing Clinical Trials Overview 260

5.170 University of Michigan Company Overview 261

5.170.1 University of Michigan Pipeline Products & Ongoing Clinical Trials Overview 261

5.171 University of Newcastle Company Overview 262

5.171.1 University of Newcastle Pipeline Products & Ongoing Clinical Trials Overview 262

5.172 University of Oslo Company Overview 263

5.172.1 University of Oslo Pipeline Products & Ongoing Clinical Trials Overview 263

5.173 University of Otago Company Overview 264

5.173.1 University of Otago Pipeline Products & Ongoing Clinical Trials Overview 264

5.174 University of South Australia Company Overview 265

5.174.1 University of South Australia Pipeline Products & Ongoing Clinical Trials Overview 265

5.175 University of Strathclyde Company Overview 266

5.175.1 University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview 266

5.176 University of Turku Company Overview 267

5.176.1 University of Turku Pipeline Products & Ongoing Clinical Trials Overview 267

5.177 University of Washington Company Overview 270

5.177.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview 270

5.178 Uppsala University Company Overview 271

5.178.1 Uppsala University Pipeline Products & Ongoing Clinical Trials Overview 271

5.179 US Biomarkers Inc Company Overview 272

5.179.1 US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 272

5.180 Vala Sciences Inc Company Overview 273

5.180.1 Vala Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 273

5.181 Vermillion Inc Company Overview 274

5.181.1 Vermillion Inc Pipeline Products & Ongoing Clinical Trials Overview 274

5.182 Vitrimark Inc (Inactive) Company Overview 276

5.182.1 Vitrimark Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 276

5.183 Vitruvian Biomedical Inc Company Overview 277

5.183.1 Vitruvian Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 277

5.184 VolitionRX Ltd Company Overview 278

5.184.1 VolitionRX Ltd Pipeline Products & Ongoing Clinical Trials Overview 278

5.185 X-Zell Inc Company Overview 279

5.185.1 X-Zell Inc Pipeline Products & Ongoing Clinical Trials Overview 279

5.186 ZORA Biosciences Oy Company Overview 280

5.186.1 ZORA Biosciences Oy Pipeline Products & Ongoing Clinical Trials Overview 280

6 Prostate Cancer- Recent Developments 281

6.1 Oct 28, 2020: Research highlights frequency of genetic risk factors among men with prostate cancer, suggests role for broader screening 281

6.2 Jul 23, 2020: PolyA-miner accurately assesses the effect of alternative polyadenylation on gene expression 281

6.3 Jul 07, 2020: The Prostate Cancer Foundation collaboration with Pan-Cancer Consortium clarifies and promotes consistent use of common terms for biomarker and germline genetic testing 282

6.4 Jun 26, 2020: Sienna Cancer Diagnostics: Change of registered office 283

6.5 Jun 24, 2020: Cancer Genetics reports first quarter 2020 financial results and provides strategic business updates 284

6.6 Jun 24, 2020: Steam treatment recommended for men with an enlarged prostate 285

6.7 Jun 11, 2020: Recent research and new multidisciplinary framework for genetic testing in prostate cancer supports broader use of panels, testing in early stage disease 286

6.8 Jun 09, 2020: Siemens and Exyte join forces to deliver integrated solutions for fast-track construction of smart biotech facilities 287

6.9 May 28, 2020: QIAGEN builds on leading position in Precision Medicine with novel solutions in oncology 288

6.10 May 18, 2020: QIAGEN announces publication of Reasoned Position Statement for proposed acquisition by Thermo Fisher and date for Annual General Meeting 289

6.11 May 15, 2020: Novus Therapeutics reports first quarter 2020 financial results 289

6.12 May 13, 2020: OPKO Health's BioReference Laboratories and Westchester Medical Center Health Network enter into strategic laboratory collaboration to deliver operational and diagnostic services 290

6.13 May 12, 2020: National Cancer Institute renews Jackson Laboratory’s Cancer Center Designation 290

6.14 May 05, 2020: InMed and Almac Group developing improved cannabinoid production methods 292

6.15 May 04, 2020: StageZero Life Sciences announces enhanced relationship with Phleb-Finders 292

6.16 Apr 24, 2020: TruSight Oncology family grows with liquid biopsy and high-throughput assay additions 292

6.17 Apr 15, 2020: J&J lifts dividend but cuts 2020 guidance 294

6.18 Apr 15, 2020: Indivumed launches global oncology alliance for personalized medicine ("Onco AI-Med") 294

6.19 Apr 15, 2020: Orion Genomics took $150,000-350,000 PPP government loan for COVID-19-struck small businesses, FOIA request shows 295

6.20 Apr 09, 2020: MDxHealth provides Q1-2020 business update 296

6.21 Apr 09, 2020: Moffitt researchers develop mathematical model to predict patient outcomes to adaptive prostate cancer therapy 297

6.22 Apr 03, 2020: NeoGenomics integrates HALO from Indica Labs 298

6.23 Mar 12, 2020: Geron reports fourth quarter and full year 2019 financial results and 2020 milestones 298

6.24 Mar 04, 2020: Adding MRI-targeted biopsy leads to more reliable diagnosis of aggressive prostate cancer 301

6.25 Mar 04, 2020: Testing with combined biopsy method improves prostate cancer diagnosis in NIH study 302

6.26 Mar 02, 2020: Anixa Biosciences announces presentation at AI and Big Data in Cancer Conference 303

6.27 Mar 02, 2020: Proscia and UCSF partner to deliver Artificial Intelligence applications that improve the accuracy and speed of cancer diagnosis 304

6.28 Feb 26, 2020: MDxHealth reports financial year 2019 results and provides outlook for 2020 305

6.29 Feb 26, 2020: bioMerieux – 2019 financial results 307

6.30 Feb 26, 2020: Adaptive Biotechnologies reports fourth quarter and full year 2019 financial results 310

6.31 Feb 26, 2020: Mayo Clinic reports 'remarkable growth' in 2019 311

6.32 Feb 18, 2020: Hologic Expands Costa Rican operations with new financial shared services center 311

6.33 Feb 14, 2020: GERON: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers 313

6.34 Feb 11, 2020: Caris Life Sciences appoints new Executive Medical Director 313

6.35 Feb 06, 2020: Epic Sciences to present new data demonstrating expanded clinical utility of AR-V7 at 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium 313

6.36 Feb 06, 2020: Myriad announces leadership transition 314

6.37 Feb 06, 2020: Myriad Genetics reports fiscal second-quarter 2020 financial results 315

6.38 Feb 05, 2020: Hologic launches new scalable options for panther system in the United States and Europe 317

6.39 Feb 03, 2020: Siemens Healthineers starts new fiscal year with strong growth – outlook confirmed 317

6.40 Jan 30, 2020: Quest Diagnostics reports record fourth quarter and full year 2019 revenues and earnings; provides guidance for full year 2020; increases dividend

5.7% to $0.56 per quarter 320

6.41 Jan 30, 2020: OGT launches breakthrough NGS panel for constitutional cytogenetics 320

6.42 Jan 23, 2020: Johnson & Johnson announces $250 million commitment to support Frontline Health Workers, reaching 100 million people by 2030 321

6.43 Jan 22, 2020: Johnson & Johnson reports 2019 fourth-quarter and full year results 322

6.44 Jan 21, 2020: Adaptive announces preliminary unaudited revenue for full year 2019 323

6.45 Jan 21, 2020: Biomark’s scientific advisor named Dean of the Schulich School of Medicine and Dentistry 324

6.46 Jan 14, 2020: Dr. Thomas P. Slavin named Senior Vice President of Medical Affairs for Myriad Oncology 324

6.47 Jan 14, 2020: Ipsen appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer 325

6.48 Jan 13, 2020: Geron announces 2019 accomplishments and key development priorities for 2020 325

6.49 Jan 13, 2020: Healthpeak announces lease with Johnson & Johnson Subsidiary at The Shore at Sierra Point 327

6.50 Jan 12, 2020: Hologic announces preliminary financial results for first quarter of fiscal 2020 327

6.51 Jan 06, 2020: Anixa Biosciences announces presentation at AACR Liquid Biopsies Conference 328

6.52 Jan 06, 2020: Sienna makes Board appointment 328

6.53 Dec 31, 2019: Biomark announces appointment of Scientific and Medical Advisors, grant of stock options and changes in Board Of Directors 329

6.54 Dec 25, 2019: GST profiteering: Rs 230-crore penalty on Johnson & Johnson 329

6.55 Dec 24, 2019: Ad-hoc announcement pursuant to article 17 market abuse regulation 329

6.56 Dec 23, 2019: Anixa Biosciences to present at Biotech Showcase 2020 330

6.57 Dec 23, 2019: Mayo Clinic names chief digital officer to lead transformative digital strategy, create Center for Digital Health 330

6.58 Dec 19, 2019: BioReference Laboratories showcases 2019 growth through the addition of cutting edge tests, greater access to services, and optimized patient experience 331

6.59 Dec 19, 2019: Biomark Diagnostics reviews 2019 and outlines plans for 2020 332

Contd…

Table

Table 1: Prostate Cancer – Pipeline Products by Stage of Development 25

Table 2: Prostate Cancer – Pipeline Products by Territory 26

Table 3: Prostate Cancer – Pipeline Products by Regulatory Path 27

Table 4: Prostate Cancer – Pipeline Products by Estimated Approval Date 28

Table 5: Prostate Cancer – Ongoing Clinical Trials 29

Table 6: Prostate Cancer Companies – Pipeline Products by Stage of Development 30

Table 7: Prostate Cancer – Pipeline Products by Stage of Development 37

Table 8: 3D Biomatrix LLC Pipeline Products & Ongoing Clinical Trials Overview 43

Table 9: 3D Cell Assay – Metastatic Prostate Cancer – Product Status 43

Table 10: 3D Cell Assay – Metastatic Prostate Cancer – Product Description 43

Table 11: A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 44

Table 12: Companion Diagnostic Test – Prostate Cancer – Product Status 44

Table 13: Companion Diagnostic Test – Prostate Cancer – Product Description 44

Table 14: Abnova Corp Pipeline Products & Ongoing Clinical Trials Overview 45

Table 15: Biomarker Test – Prostate Cancer – Product Status 45

Table 16: Biomarker Test – Prostate Cancer – Product Description 45

Table 17: AccuTech LLC Pipeline Products & Ongoing Clinical Trials Overview 46

Table 18: PSA Test – Product Status 46

Table 19: PSA Test – Product Description 46

Table 20: Acobiom Pipeline Products & Ongoing Clinical Trials Overview 47

Table 21: Companion Diagnostic Assay – Prostate Cancer – Product Status 47

Table 22: Companion Diagnostic Assay – Prostate Cancer – Product Description 47

Table 23: Advanced Marker Discovery SL Pipeline Products & Ongoing Clinical Trials Overview 48

Table 24: 2nd Generation Prostate Cancer Test – Product Status 48

Table 25: 2nd Generation Prostate Cancer Test – Product Description 48

Table 26: 3rd Generation Prostate Cancer Test – Product Status 49

Table 27: 3rd Generation Prostate Cancer Test – Product Description 49

Table 28: 4th Generation Prostate Cancer Test – Product Status 49

Table 29: 4th Generation Prostate Cancer Test – Product Description 50

Table 30: Urine Based Diagnostic Test – Prostate Cancer – Product Status 50

Table 31: Urine Based Diagnostic Test – Prostate Cancer – Product Description 50

Table 32: Affinimark Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 51

Table 33: Prostalent Diagnostic Test – Product Status 51

Table 34: Prostalent Diagnostic Test – Product Description 51

Table 35: AIT Austrian Institute of Technology GmbH Pipeline Products & Ongoing Clinical Trials Overview 52

Table 36: Biomarker Assay – Prostate Cancer – Product Status 52

Table 37: Biomarker Assay – Prostate Cancer – Product Description 52

Table 38: Albert Ludwigs University of Freiburg Pipeline Products & Ongoing Clinical Trials Overview 53

Table 39: Urine Based Non-Invasive Prostate Cancer Assay – Product Status 53

Table 40: Urine Based Non-Invasive Prostate Cancer Assay – Product Description 53

Table 41: Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 54

Table 42: NMP48 Test – Product Status 54

Table 43: NMP48 Test – Product Description 54

Table 44: Almac Diagnostic Services Ltd Pipeline Products & Ongoing Clinical Trials Overview 55

Table 45: Prostate Cancer Metastatic Assay – Product Status 55

Table 46: Prostate Cancer Metastatic Assay – Product Description 55

Table 47: Andro Diagnostics (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 56

Table 48: Diagnostic Test – Prostate Cancer – Product Status 56

Table 49: Diagnostic Test – Prostate Cancer – Product Description 56

Table 50: Anixa Diagnostics Corporation Pipeline Products & Ongoing Clinical Trials Overview 57

Table 51: Cchek – Prostate Cancer Recurrence Test – Product Status 57

Table 52: Cchek – Prostate Cancer Recurrence Test – Product Description 57

Table 53: Cchek – Prostate Cancer Treatment Monitoring Test – Product Status 58

Table 54: Cchek – Prostate Cancer Treatment Monitoring Test – Product Description 58

Table 55: Armune BioScience Inc Pipeline Products & Ongoing Clinical Trials Overview 59

Table 56: Diagnostic Test – Prostate Cancer – Product Status 59

Table 57: Diagnostic Test – Prostate Cancer – Product Description 59

Table 58: Arno Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 60

Table 59: Onapristone Companion Diagnostic Assay – Prostate Cancer – Product Status 60

Table 60: Onapristone Companion Diagnostic Assay – Prostate Cancer – Product Description 60

Table 61: Arquer Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 61

Table 62: ADXPROSTATE MCM5 ELISA Kit – Product Status 61

Table 63: ADXPROSTATE MCM5 ELISA Kit – Product Description 61

Table 64: Arrayit Corporation Pipeline Products & Ongoing Clinical Trials Overview 62

Table 65: Microarray-Based Diagnostic Test – Prostate Cancer – Product Status 62

Table 66: Microarray-Based Diagnostic Test – Prostate Cancer – Product Description 62

Table 67: Atrys Health SA Pipeline Products & Ongoing Clinical Trials Overview 63

Table 68: ProstatePredict – Product Status 63

Table 69: ProstatePredict – Product Description 63

Table 70: Atturos Pipeline Products & Ongoing Clinical Trials Overview 64

Table 71: OCProDx – Product Status 64

Table 72: OCProDx – Product Description 64

Table 73: Aurelium BioPharma Inc. Pipeline Products & Ongoing Clinical Trials Overview 65

Table 74: Prostate Cancer Screening Test – Product Status 65

Table 75: Prostate Cancer Screening Test – Product Description 65

Table 76: BARD1 Life Sciences Ltd Pipeline Products & Ongoing Clinical Trials Overview 66

Table 77: BARD1 Prostate Cancer Test – Product Status 66

Table 78: BARD1 Prostate Cancer Test – Product Description 66

Table 79: Baylor College of Medicine Pipeline Products & Ongoing Clinical Trials Overview 67

Table 80: Diagnostic Assay – Prostate Cancer – Product Status 67

Table 81: Diagnostic Assay – Prostate Cancer – Product Description 67

Table 82: Diagnostic Assay – Prostate Cancer – Product Status 68

Table 83: Diagnostic Assay – Prostate Cancer – Product Description 68

Table 84: Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 69

Table 85: UniCel DxC 600i Synchron Access – BPH-A Assay – Product Status 69

Table 86: UniCel DxC 600i Synchron Access – BPH-A Assay – Product Description 69

Table 87: Berg LLC Pipeline Products & Ongoing Clinical Trials Overview 70

Table 88: Multi-Index Diagnostic Assay – Prostate cancer – Product Status 70

Table 89: Multi-Index Diagnostic Assay – Prostate cancer – Product Description 70

Table 90: BioAffinity Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 71

Table 91: CyPath Diagnostic Assay – Prostate Cancer – Product Status 71

Table 92: CyPath Diagnostic Assay – Prostate Cancer – Product Description 71

Table 93: Biocrates Life Sciences AG Pipeline Products & Ongoing Clinical Trials Overview 72

Table 94: Metabolomic Biomarker Assay – Prostate Cancer – Product Status 72

Table 95: Metabolomic Biomarker Assay – Prostate Cancer – Product Description 72

Table 96: BioMark Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 73

Table 97: Metabolomics-based Diagnostic Assay – Prostate Cancer – Product Status 73

Table 98: Metabolomics-based Diagnostic Assay – Prostate Cancer – Product Description 74

Table 99: bioMerieux SA Pipeline Products & Ongoing Clinical Trials Overview 75

Table 100: Annexin A3 Prostate Cancer Marker – Product Status 75

Table 101: Annexin A3 Prostate Cancer Marker – Product Description 75

Table 102: Companion Diagnostic Test – Hormone-Dependent Prostate Cancer – Product Status 76

Table 103: Companion Diagnostic Test – Hormone-Dependent Prostate Cancer – Product Description 76

Table 104: Diagnostic Assay – Prostate Cancer – Product Status 76

Table 105: Diagnostic Assay – Prostate Cancer – Product Description 77

Table 106: Biosceptre International Ltd Pipeline Products & Ongoing Clinical Trials Overview 78

Table 107: BPM09 – IHC Antibody Diagnostic Assay – Product Status 78

Table 108: BPM09 – IHC Antibody Diagnostic Assay – Product Description 78

Table 109: Prostate Cancer IHC Diagnostic Test – Product Status 79

Table 110: Prostate Cancer IHC Diagnostic Test – Product Description 79

Table 111: Biotron Ltd Pipeline Products & Ongoing Clinical Trials Overview 80

Table 112: C-Test – Prostrate Cancer – Product Status 80

Table 113: C-Test – Prostrate Cancer – Product Description 80

Table 114: Blondin Bioscience, LLC Pipeline Products & Ongoing Clinical Trials Overview 81

Table 115: FACT Assay – Metastatic Prostate Cancer – Product Status 81

Table 116: FACT Assay – Metastatic Prostate Cancer – Product Description 81

Table 117: Boditech Med Inc Pipeline Products & Ongoing Clinical Trials Overview 82

Table 118: AFIAS 6 – PSA Plus Assay – Product Status 82

Table 119: AFIAS 6 – PSA Plus Assay – Product Description 82

Table 120: Boston Children's Hospital Pipeline Products & Ongoing Clinical Trials Overview 83

Table 121: Collagen XXIII Biomarker Assay – Prostate Cancer – Product Status 83

Table 122: Collagen XXIII Biomarker Assay – Prostate Cancer – Product Description 83

Table 123: Caldera Health Ltd Pipeline Products & Ongoing Clinical Trials Overview 84

Table 124: ProscaNZ – Product Status 84

Table 125: ProscaNZ – Product Description 84

Table 126: Cambridge Oncometrix Ltd Pipeline Products & Ongoing Clinical Trials Overview 85

Table 127: CAMONX CheC Test – Product Status 85

Table 128: CAMONX CheC Test – Product Description 85

Table 129: Cambridge Oncometrix Ltd – Ongoing Clinical Trials Overview 86

Table 130: CAMONX CheC Test – A Multi-centre Validation Cohort Study Evaluating the Chemical Elements Content in Semen and Expressed Prostatic Secretions in the Diagnosis and Characterisation of Prostate Cancer, in Men Identified as Having a Risk of Prostate Cancer 87

Table 131: Cancer Research Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 88

Table 132: IHC Based Test – Prostate Cancer – Product Status 88

Table 133: IHC Based Test – Prostate Cancer – Product Description 88

Table 134: Cancer Research UK Manchester Institute Pipeline Products & Ongoing Clinical Trials Overview 89

Table 135: Biomarker Test – Aggressive Prostate Cancer – Product Status 89

Table 136: Biomarker Test – Aggressive Prostate Cancer – Product Description 89

Table 137: Caris Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 90

Table 138: Diagnostic Test – PSA – Product Status 90

Table 139: Diagnostic Test – PSA – Product Description 90

Table 140: Cellanyx Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 91

Table 141: Cellanyx Test – Prostate Cancer – Product Status 91

Table 142: Cellanyx Test – Prostate Cancer – Product Description 91

Table 143: Cellmid Ltd Pipeline Products & Ongoing Clinical Trials Overview 92

Table 144: MK-ELISA Assay – Prostate Cancer – Product Status 92

Table 145: MK-ELISA Assay – Prostate Cancer – Product Description 92

Table 146: Cepheid Inc Pipeline Products & Ongoing Clinical Trials Overview 93

Table 147: Xpert Prostate CA Early Detection Test – Product Status 93

Table 148: Xpert Prostate CA Early Detection Test – Product Description 93

Table 149: Xpert Prostate Cancer Recurrence Risk Test – Product Status 94

Table 150: Xpert Prostate Cancer Recurrence Risk Test – Product Description 94

Table 151: Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 95

Table 152: Nanotrap Prostate Cancer Biomarker Test – Product Status 95

Table 153: Nanotrap Prostate Cancer Biomarker Test – Product Description 95

Table 154: ChemImage Corp Pipeline Products & Ongoing Clinical Trials Overview 96

Table 155: Prognostic Test – Prostate Cancer – Product Status 96

Table 156: Prognostic Test – Prostate Cancer – Product Description 96

Table 157: China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 97

Table 158: Diagnostic Kit – Human Prostate Specific Antigen – Product Status 97

Table 159: Diagnostic Kit – Human Prostate Specific Antigen – Product Description 97

Table 160: Chronix Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 98

Table 161: Companion Diagnostic Test – Prostate Cancer – Product Status 98

Table 162: Companion Diagnostic Test – Prostate Cancer – Product Description 98

Table 163: Cleveland Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 99

Table 164: IsoPSA Assay – Product Status 99

Table 165: IsoPSA Assay – Product Description 99

Table 166: CompanDX Ltd Pipeline Products & Ongoing Clinical Trials Overview 100

Table 167: Biomarker Assay – Prostate Cancer – Product Status 100

Table 168: Biomarker Assay – Prostate Cancer – Product Description 100

Table 169: Contango Asset Management Ltd Pipeline Products & Ongoing Clinical Trials Overview 101

Table 170: Prostate Cancer Diagnostic Test – Product Status 101

Table 171: Prostate Cancer Diagnostic Test – Product Description 101

Table 172: Cornell University Pipeline Products & Ongoing Clinical Trials Overview 102

Table 173: NEAT 1 Assay – Prostate Cancer – Product Status 102

Table 174: NEAT 1 Assay – Prostate Cancer – Product Description 102

Table 175: Courtagen Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 103

Table 176: Prostate Cancer Diagnostic Panel – Product Status 103

Table 177: Prostate Cancer Diagnostic Panel – Product Description 103

Table 178: CS-Keys, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 104

Table 179: caPCNA – Prostate Cancer – Product Status 104

Table 180: caPCNA – Prostate Cancer – Product Description 104

Table 181: Cytosystems Ltd Pipeline Products & Ongoing Clinical Trials Overview 105

Table 182: BladderLight – Prostate Cancer – Product Status 105

Table 183: BladderLight – Prostate Cancer – Product Description 105

Table 184: Detroit R&D, Inc. Pipeline Products & Ongoing Clinical Trials Overview 106

Table 185: Oligosaccharide-Related Prostate Cancer Biomarker Assay – Product Status 106

Table 186: Oligosaccharide-Related Prostate Cancer Biomarker Assay – Product Description 106

Table 187: Elypta AB Pipeline Products & Ongoing Clinical Trials Overview 107

Table 188: Elypta Liquid Biopsy Kit – Prostate Cancer – Product Status 107

Table 189: Elypta Liquid Biopsy Kit – Prostate Cancer – Product Description 107

Table 190: Emory University Pipeline Products & Ongoing Clinical Trials Overview 108

Table 191: Diagnostic Test – Prostate Cancer – Product Status 108

Table 192: Diagnostic Test – Prostate Cancer – Product Description 108

Table 193: Entopsis LLC Pipeline Products & Ongoing Clinical Trials Overview 109

Table 194: OpsisDx Test – Prostate Cancer – Product Status 109

Table 195: OpsisDx Test – Prostate Cancer – Product Description 109

Table 196: Epigenomics AG Pipeline Products & Ongoing Clinical Trials Overview 110

Table 197: Biomarker PITX2 – Prostate Cancer Prognosis – Product Status 110

Table 198: Biomarker PITX2 – Prostate Cancer Prognosis – Product Description 110

Table 199: Euclid Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 111

Table 200: Diagnostic Test – Prostate Cancer – Product Status 111

Table 201: Diagnostic Test – Prostate Cancer – Product Description 111

Table 202: Eurobio Scientific SA Pipeline Products & Ongoing Clinical Trials Overview 112

Table 203: EHT Dx13 – Product Status 112

Table 204: EHT Dx13 – Product Description 112

Table 205: Eventus Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 113

Table 206: Octava Test – Prostate Cancer – Product Status 113

Table 207: Octava Test – Prostate Cancer – Product Description 113

Table 208: Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 114

Table 209: Liquid Biopsy Test – Prostate Cancer – Product Status 114

Table 210: Liquid Biopsy Test – Prostate Cancer – Product Description 114

Table 211: Exiqon AS Pipeline Products & Ongoing Clinical Trials Overview 115

Table 212: Prognosis Test – Prostate Cancer – Product Status 115

Table 213: Prognosis Test – Prostate Cancer – Product Description 115

Table 214: Exosome Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 116

Table 215: Diagnostic Assay – Arv7 – Product Status 116

Table 216: Diagnostic Assay – Arv7 – Product Description 116

Table 217: Exosome Diagnostics Inc – Ongoing Clinical Trials Overview 117

Table 218: Diagnostic Assay – Arv7 – Detection of ARv7 in the Plasma of Men with Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP) 118

Table 219: Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview 119

Table 220: ExoTEST Prostate Cancer – Product Status 119

Table 221: ExoTEST Prostate Cancer – Product Description 119

Table 222: Fluxion Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 120

Table 223: IsoFlux CTC Liquid Biopsy System – Prostate Cancer – Product Status 120

Table 224: IsoFlux CTC Liquid Biopsy System – Prostate Cancer – Product Description 120

Table 225: Fred Hutchinson Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 121

Table 226: Genomic Panel Prediction Test – Metastatic-Lethal Prostate Cancer – Product Status 121

Table 227: Genomic Panel Prediction Test – Metastatic-Lethal Prostate Cancer – Product Description 121

Table 228: French National Institute of Health and Medical Research Pipeline Products & Ongoing Clinical Trials Overview 122

Table 229: Protein Receptor Based Diagnostic Assay – Prostate Cancer – Product Status 122

Table 230: Protein Receptor Based Diagnostic Assay – Prostate Cancer – Product Description 122

Table 231: Genomic Health Inc Pipeline Products & Ongoing Clinical Trials Overview 123

Table 232: Negative Biopsy Test – Prostate Cancer – Product Status 123

Table 233: Negative Biopsy Test – Prostate Cancer – Product Description 123

Table 234: Next Generation Sequencing Oncotype DX – Prostate Cancer Assay – Product Status 124

Table 235: Next Generation Sequencing Oncotype DX – Prostate Cancer Assay – Product Description 124

Table 236: Georgia Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 125

Table 237: Diagnostic Biomarker Test – Prostate Cancer – Product Status 125

Table 238: Diagnostic Biomarker Test – Prostate Cancer – Product Description 125

Table 239: Gilupi GmbH Pipeline Products & Ongoing Clinical Trials Overview 126

Table 240: Diagnostic Test – Prostate Cancer – Product Status 126

Table 241: Diagnostic Test – Prostate Cancer – Product Description 126

Table 242: GlyCa BioSciences Inc Pipeline Products & Ongoing Clinical Trials Overview 127

Table 243: Carbohydrate Biomarker – Prostate Cancer – Product Status 127

Table 244: Carbohydrate Biomarker – Prostate Cancer – Product Description 127

Table 245: GlycoZym USA Inc Pipeline Products & Ongoing Clinical Trials Overview 128

Table 246: Diagnostic Assay – Prostate Cancer – Product Status 128

Table 247: Diagnostic Assay – Prostate Cancer – Product Description 128

Table 248: Gregor Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 129

Table 249: Screening Test – Prostate Cancer – Product Status 129

Table 250: Screening Test – Prostate Cancer – Product Description 129

Table 251: H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 130

Table 252: H2AX Gene Based Diagnostic Test – Prostate Cancer – Product Status 130

Table 253: H2AX Gene Based Diagnostic Test – Prostate Cancer – Product Description 130

Table 254: H. Lee Moffitt Cancer Center & Research Institute Inc – Ongoing Clinical Trials Overview 131

Table 255: H2AX Gene Based Diagnostic Test – Prostate Cancer – Assess Gamma H2ax Positivity in Circulating Prostate Cancer Cells Before and after Radium 223 Treatment 132

Table 256: HealthTell Inc Pipeline Products & Ongoing Clinical Trials Overview 133

Table 257: ImmunoSignature Test – Prostate Cancer – Product Status 133

Table 258: ImmunoSignature Test – Prostate Cancer – Product Description 133

Table 259: Hologic Inc Pipeline Products & Ongoing Clinical Trials Overview 134

Table 260: Second-Generation Prostate Cancer Assay – Product Status 134

Table 261: Second-Generation Prostate Cancer Assay – Product Description 134

Table 262: Ikonisys Inc Pipeline Products & Ongoing Clinical Trials Overview 135

Table 263: oncoFISH prostate – Product Status 135

Table 264: oncoFISH prostate – Product Description 135

Table 265: Imagion Biosystems Inc Pipeline Products & Ongoing Clinical Trials Overview 136

Table 266: MagSense Prostate Cancer Test – Product Status 136

Table 267: MagSense Prostate Cancer Test – Product Description 136

Table 268: Immunovia AB Pipeline Products & Ongoing Clinical Trials Overview 137

Table 269: IMMray – Prostate Cancer – Product Status 137

Table 270: IMMray – Prostate Cancer – Product Description 137

Table 271: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 138

Table 272: Biosensor Test – Product Status 138

Table 273: Biosensor Test – Product Description 138

Table 274: InterGenetics Inc Pipeline Products & Ongoing Clinical Trials Overview 139

Table 275: OncoVue Prostate – Product Status 139

Table 276: OncoVue Prostate – Product Description 139

Table 277: IRIS International Inc Pipeline Products & Ongoing Clinical Trials Overview 140

Table 278: NADIA – Prostate Cancer – Product Status 140

Table 279: NADIA – Prostate Cancer – Product Description 140

Table 280: Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 141

Table 281: 5hmC Marker Assay – Prostate Cancer – Product Status 141

Table 282: 5hmC Marker Assay – Prostate Cancer – Product Description 141

Table 283: Biomarker Assay – Protein C Inhibitor – Product Status 142

Table 284: Biomarker Assay – Protein C Inhibitor – Product Description 142

Table 285: Blood Based Diagnostic Assay – Prostate Cancer – Product Status 142

Table 286: Blood Based Diagnostic Assay – Prostate Cancer – Product Description 143

Table 287: Diagnostic And Prognostic Assay – Aggressive Prostate Cancer – Product Status 143

Table 288: Diagnostic And Prognostic Assay – Aggressive Prostate Cancer – Product Description 143

Table 289: Protein Biomarker Assay – Aggressive Prostate Cancer – Product Status 144

Table 290: Protein Biomarker Assay – Aggressive Prostate Cancer – Product Description 144

Table 291: Serum-Based Assay – Prostate Cancer – Product Status 144

Table 292: Serum-Based Assay – Prostate Cancer – Product Description 145

Table 293: KineMed Inc Pipeline Products & Ongoing Clinical Trials Overview 146

Table 294: Diagnostic Assay – Prostate Cell Proliferation – Product Status 146

Table 295: Diagnostic Assay – Prostate Cell Proliferation – Product Description 146

Table 296: L2 Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 147

Table 297: Multiplex SNP Assay – Prostate Cancer – Product Status 147

Table 298: Multiplex SNP Assay – Prostate Cancer – Product Description 147

Table 299: Lantern Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview 148

Table 300: Companion Diagnostic Test – Irofulven-1 – Product Status 148

Table 301: Companion Diagnostic Test – Irofulven-1 – Product Description 148

Table 302: Lynx Design, Inc. Pipeline Products & Ongoing Clinical Trials Overview 149

Table 303: Urine Test – Prostate Cancer – Product Status 149

Table 304: Urine Test – Prostate Cancer – Product Description 149

Table 305: MabCure Inc Pipeline Products & Ongoing Clinical Trials Overview 150

Table 306: Diagnostic Test – Prostate Cancer – Product Status 150

Table 307: Diagnostic Test – Prostate Cancer – Product Description 150

Table 308: MacroArray Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 151

Table 309: HGPIN-1 – Product Status 151

Table 310: HGPIN-1 – Product Description 151

Table 311: PCADM-1 – Product Status 152

Table 312: PCADM-1 – Product Description 152

Table 313: PCADM-2 – Product Status 152

Table 314: PCADM-2 – Product Description 153

Table 315: MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 154

Table 316: Diagnostic Assay – Asymptomatic Prostate Cancer – Product Status 154

Table 317: Diagnostic Assay – Asymptomatic Prostate Cancer – Product Description 154

Table 318: Prognostic Test – Prostate Cancer – Product Status 155

Table 319: Prognostic Test – Prostate Cancer – Product Description 155

Table 320: MDxHealth SA Pipeline Products & Ongoing Clinical Trials Overview 156

Table 321: InformMDx – Prostate Cancer CLIA Test – Product Status 156

Table 322: InformMDx – Prostate Cancer CLIA Test – Product Description 157

Table 323: InformMDx Prognostic Test – Prostate Cancer – Product Status 157

Table 324: InformMDx Prognostic Test – Prostate Cancer – Product Description 157

Table 325: MonitorMDx – Prostate Cancer – Product Status 158

Table 326: MonitorMDx – Prostate Cancer – Product Description 158

Table 327: RecurMDx – Prostate Cancer – Product Status 158

Table 328: RecurMDx – Prostate Cancer – Product Description 159

Table 329: Metabolomic Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 160

Table 330: ProstateDx – Product Status 160

Table 331: ProstateDx – Product Description 160

Table 332: Metanomics Health GmbH Pipeline Products & Ongoing Clinical Trials Overview 161

Table 333: Prognostic Assay – Prostate Cancer – Product Status 161

Table 334: Prognostic Assay – Prostate Cancer – Product Description 161

Table 335: MetaStat Inc Pipeline Products & Ongoing Clinical Trials Overview 162

Table 336: MenaCalc Prostate – Product Status 162

Table 337: MenaCalc Prostate – Product Description 162

Table 338: Micromedic Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 163

Table 339: CellDetect – Prostate Cancer – Product Status 163

Table 340: CellDetect – Prostate Cancer – Product Description 163

Table 341: Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview 164

Table 342: Immunoassay – Prostate Cancer – Product Status 164

Table 343: Immunoassay – Prostate Cancer – Product Description 164

Table 344: Minomic International Ltd Pipeline Products & Ongoing Clinical Trials Overview 165

Table 345: MiCheck – LDT – Product Status 165

Table 346: MiCheck – LDT – Product Description 165

Table 347: MiCheck Prostate Cancer Test – Product Status 166

Table 348: MiCheck Prostate Cancer Test – Product Description 166

Table 349: Myriad Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 167

Table 350: myPath Prostate Cancer – Product Status 167

Table 351: myPath Prostate Cancer – Product Description 167

Table 352: Myriad International GmbH Pipeline Products & Ongoing Clinical Trials Overview 168

Table 353: Diagnostic Assay – Prostate Cancer – Product Status 168

Table 354: Diagnostic Assay – Prostate Cancer – Product Description 168

Table 355: Nano Discovery Inc. Pipeline Products & Ongoing Clinical Trials Overview 169

Table 356: NanoDLSay – Prostate Cancer – Product Status 169

Table 357: NanoDLSay – Prostate Cancer – Product Description 169

Table 358: Nanocytomics LLC Pipeline Products & Ongoing Clinical Trials Overview 170

Table 359: PWS Nanocytology System – Prostate Cancer – Product Status 170

Table 360: PWS Nanocytology System – Prostate Cancer – Product Description 170

Table 361: NanoIVD Inc Pipeline Products & Ongoing Clinical Trials Overview 171

Table 362: Prostate CancerCheck – Product Status 171

Table 363: Prostate CancerCheck – Product Description 171

Table 364: Nanostics Inc Pipeline Products & Ongoing Clinical Trials Overview 172

Table 365: ClarityDX Prostate – Product Status 172

Table 366: ClarityDX Prostate – Product Description 172

Table 367: Nanostics Inc – Ongoing Clinical Trials Overview 173

Table 368: ClarityDX Prostate – Clinical Validation of ClarityDX Prostate as a Reflex Test to Prostate Specific Antigen (PSA) to Refine the Prediction of Clinically-significant Prostate Cancer 174

Table 369: NeuroBioTex Inc Pipeline Products & Ongoing Clinical Trials Overview 175

Table 370: Prostate Cancer Home Screening Test – Product Status 175

Table 371: Prostate Cancer Home Screening Test – Product Description 175

Table 372: Nonagen Bioscience Corp Pipeline Products & Ongoing Clinical Trials Overview 176

Table 373: Diagnostic Assay – Prostate Cancer – Product Status 176

Table 374: Diagnostic Assay – Prostate Cancer – Product Description 176

Table 375: Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 177

Table 376: Biomarker Test – Prostate Cancer – Product Status 177

Table 377: Biomarker Test – Prostate Cancer – Product Description 177

Table 378: NovaGray Pipeline Products & Ongoing Clinical Trials Overview 178

Table 379: NovaGray Prostate Test – Product Status 178

Table 380: NovaGray Prostate Test – Product Description 178

Table 381: Novel Bio-spectrum Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 179

Table 382: NBT Diagnostic Test – Prostate Cancer – Product Status 179

Table 383: NBT Diagnostic Test – Prostate Cancer – Product Description 179

Table 384: Nuclea Biotechnologies Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 180

Table 385: Decision Dx – Prostate Cancer – Product Status 180

Table 386: Decision Dx – Prostate Cancer – Product Description 180

Table 387: USP2a Diagnostic Assay – Prostate Cancer – Product Status 181

Table 388: USP2a Diagnostic Assay – Prostate Cancer – Product Description 181

Table 389: Numares AG Pipeline Products & Ongoing Clinical Trials Overview 182

Table 390: AXINON Test – Prostate Cancer – Product Status 182

Table 391: AXINON Test – Prostate Cancer – Product Description 182

Table 392: NuView Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 183

Table 393: NV-VPAC1 – Prostate Cancer – Product Status 183

Table 394: NV-VPAC1 – Prostate Cancer – Product Description 183

Table 395: NuView Life Sciences Inc – Ongoing Clinical Trials Overview 184

Table 396: NV-VPAC1 – Prostate Cancer – Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones 185

Table 397: Olympia Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 186

Table 398: PCa-Dx – Product Status 186

Table 399: PCa-Dx – Product Description 186

Table 400: PCa-Mx – Product Status 187

Table 401: PCa-Mx – Product Description 187

Table 402: PCa-Px – Product Status 187

Table 403: PCa-Px – Product Description 188

Table 404: PCa-Sx – Product Status 188

Table 405: PCa-Sx – Product Description 188

Table 406: PCa-Tx – Product Status 189

Table 407: PCa-Tx – Product Description 189

Table 408: Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 190

Table 409: EarlyCDT Prostate Cancer Test – Product Status 190

Table 410: EarlyCDT Prostate Cancer Test – Product Description 190

Table 411: OncoCyte Corp Pipeline Products & Ongoing Clinical Trials Overview 191

Table 412: PanC-Dx – Prostate Cancer – Product Status 191

Table 413: PanC-Dx – Prostate Cancer – Product Description 191

Table 414: Onconome, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 192

Table 415: ProstaMark EPCA Tissue Assay – Product Status 192

Table 416: ProstaMark EPCA Tissue Assay – Product Description 192

Table 417: ProstaMark EPCA-2 Serum Assay – Product Status 193

Table 418: ProstaMark EPCA-2 Serum Assay – Product Description 193

Table 419: ONCOVEDA Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 194

Table 420: Diagnostic Test – Prostate Cancer – Product Status 194

Table 421: Diagnostic Test – Prostate Cancer – Product Description 194

Table 422: OncoVista Innovative Therapies Inc Pipeline Products & Ongoing Clinical Trials Overview 195

Table 423: OVI-117 Biomarker – Prostate Cancer – Product Status 195

Table 424: OVI-117 Biomarker – Prostate Cancer – Product Description 195

Table 425: On-Q-ity, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 196

Contd…

Figures